Literature DB >> 26181011

Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015.

Carlo Gambacorti-Passerini1, Rocco Piazza2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26181011     DOI: 10.1001/jamaoncol.2015.50

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN: 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  4 in total

1.  How "precise" is precision medicine in hematology?

Authors:  Carlo Gambacorti-Passerini; Rocco Piazza
Journal:  Haematologica       Date:  2017-01       Impact factor: 9.941

2.  Economic Evaluations of Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia in Middle- and High-Income Countries: A Systematic Review.

Authors:  Jie Fu; Yuchen Liu; Houwen Lin; Bin Wu
Journal:  Clin Drug Investig       Date:  2018-12       Impact factor: 2.859

3.  Salidroside enhances the anti-cancerous effect of imatinib on human acute monocytic leukemia via the induction of autophagy-related apoptosis through AMPK activation.

Authors:  Chiyu Ge; Junli Zhang; Feng Feng
Journal:  RSC Adv       Date:  2019-08-12       Impact factor: 4.036

4.  Outcome of pediatric chronic myeloid leukemia with management focusing on the monitoring of BCR-ABL fusion gene transcript levels.

Authors:  Ibrahim Al-Ghemlas; Saad Al-Daama; Hawazin Aqueel; Khawar Siddiqui; Hassan El-Solh; Hala Omer; Loloah AlRajeh; Amal Al-Seraihy; Ali Alahmari; Hawazen AlSaedi; Awatif AlAnazi; Mouhab Ayas
Journal:  Int J Pediatr Adolesc Med       Date:  2022-06-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.